NICE rejects Sanofi’s Cablivi in draft guidelines
Trial data does not show whether adding Cablivi to standard care improves either length or quality of life over the long term, the Institute said
Read More
Tag: caplacizumab
Cablivi gets positive results for rare blood clotting disorder
Sanofi’s Cablivi has been linked with a 74% reduction in aTTP-related death in a Phase III trial published by the New England Journal of Medicine.
Read More
Sanofi’s Cablivi cleared for rare bleeding disorder
Patients with the rare clotting disorder acquired thrombotic thrombocytopenic purpura (aTTP) have gained a new treatment option in Europe with the approval of Sanofi’s Cablivi.
Read More
Sanofi snaps up Ablynx for 3.9bn euros
Sanofi has announced its intention to buy Belgian drugmaker Ablynx via a deal valued at around 3.9 billion Euros, beating Novo Nordisk to the finish line.
Read More
Novo makes second move on Ablynx
Novo Nordisk is switching up a gear its efforts to acquire Belgian biopharma Ablynx, with a heightened offer valued at around 2.6 billion euros.
Read More
Ablynx files caplacizumab for ultra rare blood disorder
Patients in Europe with the ultra rare blood clotting disorder acquired thrombotic thrombocytopenic purpura (aTTP) are a step closer to getting the first therapeutic specifically indicated for treating the disease, after Ablynx filed for approval of caplacizumab.
Read More
- Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
- IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
- En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
- ALK’s EURneffy receives positive CHMP opinion for emergency anaphylaxis treatment in children
- CERo reports encouraging early data from phase 1 trial of CER‑1236
